Wednesday, April 19, 2017 / 18:00 – 19:30

Bristol-Myers Squibb: Immuno-Oncology: Emerging Data and Advancing Clinical Research in Hepatocellular Carcinoma

Amtrium 1

Chair:

Bruno SANGRO, Spain

18:00 – 18:05

Welcome and Introductions

Bruno SANGRO, Spain

18:05 – 18:20

Scientific Rationale and Potential for Immuno-Oncology (I-O) in HCC

Bruno SANGRO, Spain

18:20 – 18:45

Emerging Clinical Data in the Treatment of Advanced HCC

Jörg TROJAN, Germany

18:45 – 19:00

Potential of I-O Agents in Combination Therapy

Jean-François DUFOUR, Switzerland

19:00 – 19:20

Relevance of Biomarkers in HCC

Katie KELLEY, United States

19:20 – 19:30

Meeting Close and Q&A

Bruno SANGRO, Spain

Wednesday, April 19, 2017 / 18:00 – 19:30

Genfit: Advances in biomarkers and trial endpoints for NASH and liver fibrosis

Elicium 1

Chairs:

Stephen A. HARRISON, United States

Vlad RATZIU, France

18:00 – 18:20

Insights on dynamic biomarkers for NASH and liver fibrosis

Rohit LOOMBA, United States

18:20 – 18:40

New imaging methods ready for prime-time

Manuel ROMERO-GOMEZ, Spain

18:40 – 19:00

Current and future algorithms to identify patients at risk

Quentin Mark ANSTEE, United Kingdom

19:00 – 19:20

Histological surrogate endpoints: building on solid ground

Vlad RATZIU, France

19:20 – 19:30

Concluding remarks, Q&A

Stephen A. HARRISON, United States

Vlad RATZIU, France

Wednesday, April 19, 2017 / 18:00 – 19:30

Norgine: Improving outcomes in HE: Time to take action

Elicium 2

Chair:

Jasmohan BAJAJ,
United States

18:00 – 18:05

Welcome and introductions

Jasmohan BAJAJ, United States

18:05 – 18:25

HE: The last complication standing?

Aleksander KRAG, Denmark

18:25 – 18:30

Living with HE: Patient experience (Patient videos)

18:30 – 18:50

HE readmission: The next frontier

Jasmohan BAJAJ, United States

18:50 – 19:10

A multidisciplinary approach

Simone STRASSER, Australia

19:10 – 19:20

A passport to support the patient journey

Jasmohan BAJAJ, United States

19:20 – 19:30

Q&A and panel discussion

Jasmohan BAJAJ, United States (Chair)

Aleksander KRAG, Denmark

Simone STRASSER, Australia

Thursday, April 20, 2017 / 07:30 – 08:30

Allergan: Global impact and clinical management of NASH

Emerald

Chair:

Quentin Mark ANSTEE, United Kingdom

07:30 – 07:32

Introductions to symposium objectives, topics and panellists

Quentin Mark ANSTEE, United Kingdom

07:32 – 07:44

Global and regional impact of NASH

Anna Mae DIEHL, United States

07:44 – 07:56

Clinical diagnosis of NASH through non-invasive and invasive assessments

Quentin Mark ANSTEE, United Kingdom

07:56 – 08:08

Considerations for pharmacological intervention in NASH

Vlad RATZIU, France

08:08 – 08:16

Overview of Allergan NASH clinical program

Eric LEFEBVRE, United States

08:16 – 08:30

Management of NASH patients through case study

Quentin Mark ANSTEE, United Kingdom

Anna Mae DIEHL, United States

Eric LEFEBVRE, United States

Vlad RATZIU, France

Thursday, April 20, 2017 / 07:30 – 08:30

Gilead: Going beyond, together in HBV care

Elicium 2

Chair:

Harry L.A. JANSSEN, Canada

07:30 – 07:33

Introduction

Harry L.A. JANSSEN, Canada

07:33 – 07:48

Going beyond current expectations of HBV treatment

Henry Lik Yuen Chan, Hong Kong, China

07:48 – 08:03

Going beyond current expectations for patient outcomes

Harry L.A. JANSSEN, Canada

08:03 – 08:18

Going beyond management towards cure

Joerg PETERSEN, Germany

08:18 – 08:28

Going beyond, together

Harry L.A. JANSSEN, Canada (Chair)

Henry Lik Yuen Chan, Hong Kong

Joerg PETERSEN, Germany

08:28 – 08:30

Summary

Harry L.A. JANSSEN, Canada

Thursday, April 20, 2017 / 18:30 – 20:00

Gilead: Going beyond, together in HCV care

Hall 5

Chairs:

Joost Ph DRENTH,

The Netherlands

Stefan ZEUZEM, Germany

18:30 – 18:40

Welcome and introduction

Joost Ph DRENTH, The Netherlands

18:40 – 18:55

Going beyond expectations of treatment

Edward GANE, New Zealand

18:55 – 19:10

Going beyond expectations in real-world practice

Jose Luis CALLEJA, Spain

19:10 – 19:25

Going beyond expectations for patient outcomes

Stefano FAGIUOLI, Italy

19:25 – 19:40

Going beyond cure through collaboration

Joost Ph DRENTH, The Netherlands

19:40 – 19:55

Going beyond expectations through exchange

Stefan ZEUZEM, Germany (Chair)

Jose Luis CALLEJA, Spain

Joost Ph DRENTH, The Netherlands

Stefano FAGIUOLI, Italy

Edward GANE, New Zealand

19:55 – 20:00

Summary

Stefan ZEUZEM, Germany

Thursday, April 20, 2017 / 18:30 – 20:00

Intercept: Changing perspectives in cholestatic liver disease and PBC

Amtrium 1

Chair:

Ulrich BEUERS,

The Netherlands

18:30 – 18:35

Chair’s welcome and introductions

Ulrich BEUERS, The Netherlands

18:35 – 18:50

A panoramic view of cholestatic liver disease

Gideon HIRSCHFIELD, United Kingdom

18:50 – 19:10

Focusing in on PBC: Novel targets for future management

Michael TRAUNER, Austria

19:10 – 19:30

Painting the new treatment landscape: Novel and emerging therapies for PBC

Frederik NEVENS, Belgium

19:30 – 19:45

Challenging clinical cases in PBC

Gideon HIRSCHFIELD, United Kingdom

19:45 – 19:55

Panel discussion / Q&A

Ulrich BEUERS, The Netherlands (Chair)

Gideon HIRSCHFIELD, United Kingdom

Frederik NEVENS, Belgium

Michael TRAUNER, Austria

19:55 – 20:00

Summary and close of meeting

Ulrich BEUERS, The Netherlands

Friday, April 21, 2017 / 18:30 – 20:00

AbbVie: HCV 2017: Has the pan-genotypic era arrived?

Hall 5

Chairs:

Ira JACOBSON,
United States

Stefan ZEUZEM, Germany

18:30 – 18:35

Welcome and introduction

Stefan ZEUZEM, Germany

18:35 – 18:55

Understanding the current HCV treatment paradigm

Ira JACOBSON, United States

18:55 – 19:15

Embracing the pan-genotypic treatment paradigm

Robert BROWN, United States

19:15 – 19:35

Future impact of pan-genotypic regimens on HCV management and eradication

Stefan ZEUZEM, Germany

19:35 – 19:55

Audience Q&A

Ira JACOBSON, United States

Stefan ZEUZEM, Germany

19:55 – 20:00

Summary and close

Ira JACOBSON, United States

Friday, April 21, 2017 / 18:30 – 20:00

MSD: Two Sides of the Coin: Discussing Perspectives on HCV Treatment

Auditorium

Introduction Chair:

Kosh AGARWAL, United Kingdom

18:30 – 18:50

1st Session-“Bridging the gaps in HCV treatment”

Chair: Kosh AGARWAL, United Kingdom

18:30 – 18:40

What we learned from scientific studies

Heiner WEDEMEYER, Germany

18:40 – 18:50 What we learned from real world data

Nancy S REAU, United States

18:50 – 19:00

Panel discussion

All

19:00 – 19:20

2nd Session-“Renal Impairment in HCV: Two Points of View”

Chair: Kosh AGARWAL, United Kingdom

19:00 – 19:10

Hepatologist perspective

Stanislas POL, France

19:10 – 19:20

Nephrologist perspective

Fabrizio FABRIZI, Italy

19:20 – 19:30

Panel discussion

All

19:30 – 19:50

3nd Session-“HCV in People Who Inject Drugs: On the Path to Elimination”

Chair: Kosh AGARWAL, United Kingdom

19:30 – 19:40

What we learned from scientific studies

Gregory DORE, Australia

19:40 – 19:50

What we learned from real world data

Brian CONWAY, Canada

19:50 – 20:00

Panel discussion

All

Saturday, April 22, 2017 / 07:00 – 08:00

Cepheid: Revolutionizing the management of HCV in high risk populations – linkage to care through point-of-care molecular testing

G102

07:00 – 07:15

Case finding, diagnosis, referral and elimination strategies for viral hepatitis

Geoffrey DUSHEIKO, United Kingdom

07:15 – 07:30

Enhancing testing for hepatitis C virus infection through simplified point-of-care diagnostics

Jason GREBELY, Australia

07:30 – 07:45

Advancing the goalpost: HCV RNA detection in finger prick blood for point-of-care applications

Anna Maria GERETTI, United Kingdom

07:45 – 08:00

HCV molecular point-of-care testing in high risk populations: experience in a prison setting

Celia AITKEN, United Kingdom

Saturday, April 22, 2017 / 12:30 – 14:00

AbbVie: Simplifying and Shortening HCV Treatment: An interactive Debate

Auditorium

Chair:

Jean-Michel PAWLOTSKY, France

12:30 – 12:45

Welcome and introduction

Jean-Michel PAWLOTSKY, France

12:45 – 13:30

Discussion and informal debate: “Simplifying and shortening HCV treatment”

Jean-Michel PAWLOTSKY, France

Fred POORDAD, United States

Simone STRASSER, Australia

13:30 – 13:55

Audience Q&A

Jean-Michel PAWLOTSKY, France

13:55 – 14:00

Summary and close

Jean-Michel PAWLOTSKY, France

Saturday, April 22, 2017 / 18:30 – 20:00

Sirtex: New evidence for the use of SIR-Spheres® Y-90 resin microspheres vs sorafenib in unresectable HCC

Forum

Chairs:

René ADAM, France

Bruno SANGRO, Spain

18:30 – 18:35

Welcome and introduction

René ADAM, France

Bruno SANGRO, Spain

18:35 – 18:45

Addressing patient needs in HCC — What is the role of SIRT?

Panos KANAVOS, United Kingdom

18:45 – 19:10

The SARAH study results

Valérie Vilgrain, France

19:10 – 19:20

Study designs of SIRveNIB, VESPRO & SORAMIC

Jens RICKE, Germany

19:20 – 19:35

Use of SIR-Spheres Y-90 resin microspheres to downstage HCC for surgery

Antonio D. PINNA, Italy

19:35 – 20:00

Panel discussion

René ADAM, France

Mohammed BOUATTOUR, France

Panos KANAVOS, United Kingdom

Antonio D. PINNA, Italy

Jens RICKE, Germany

Bruno SANGRO, Spain

Chris VERSLYPE, Belgium

Valérie Vilgrain, France

 

Saturday, April 22, 2017 / 07:30 – 08:30

Galmed: NASH fibrosis – From Pathology to Treatement

G107

Chair:

Arun SANYAL,
United States

07:30 – 07:50

The pathogenesis of NASH – Insights into potential targets for treatment of steatosis, inflammation and fibrosis

Vlad RATZIU, France

07:50 – 08:10

Aramchol – Treating NASH through prevention and reversal of fibrosis

Jose M. MATO, Spain

Shimon REIF, Israel

08:10 – 08:30

Aramchol – From scientific rational to clinical development for NASH and beyond

Rohit LOOMBA, United States

Saturday, April 22, 2017 / 18:30 – 19:30

OWL: NASH in the spotlight: a metabolomics approach

G107

Chairs:

Pierre BEDOSSA, France

José M Mato, Spain

18:30 – 18:45

A metabocentric approach to NAFLD

José M Mato, Spain

18:45 – 18:50

Q&A

José M Mato, Spain

18:50 – 19:05

NASH diagnosis in type 2 diabetes mellitus

Miriam PÉREZ, Spain

19:05 – 19:10

Q&A

Miriam PÉREZ, Spain

19:10 – 19:25

The impact of bariatric surgery on NAFLD

Carmit NETANEL, Israel

19:25 – 19:30

Q&A

Carmit NETANEL, Israel

Saturday, April 22, 2017 / 18:30 – 20:00

UNIVAR: A Discussion on the Management of Wilsons Disease

G105

Chair:

Peter FERENCI, Austria

18:30 – 18:40

Chair and opening remarks

Peter FERENCI, Austria

18:40 – 18:55

What is the mark of success in treating Wilson’s Disease patients?

Gideon HIRSCHFIELD, United Kingdom

18:55 – 19:15

Management of Wilson’s Disease in paediatrics population, including the role of transplant

Anil DHAWAN, United Kingdom

19:15 – 19:35

How to manage difficult situations when dealing with Wilson’s Disease patients

Karl Heinz WEISS, Germany

19:35 – 19:50

Managing difficult cases of Wilson’s Disease

Anil DHAWAN, United Kingdom

Peter FERENCI, Austria

Gideon HIRSCHFIELD, United Kingdom

Karl Heinz WEISS, Germany

19:50 – 20:00

Close and summary

Peter FERENCI, Austria